IMBRUVICA® U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia
ABBVie announced today that the U.S. Food and Drug Administration approved the update of the IMBRUVICA ® Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia based on the final analysis of the Phase 3 iNNOVATE study. First approved in 2013, IMBRUVICA is currently available to patients with several types of … – ABBVie (NYSE: ABBV) announced today that the U.S. Food and Drug Admini...
Meletiosa Dimopoulos Danelle James Abbvie Company Janssen Biotech Inc Global Development Drug Administration
Source: investingnews.com